Saturday, July 11, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “treatment”

2,520 pharma patents match "treatment" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 2,520
Index total 30,257
Page 79 / 105

Quick answer

This filtered view shows 2,520 pharmaceutical patents matching "treatment" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

2,520 results for “treatment” · 30,257 patents in full index Clear search

  1. US 8569225

    Targeting complement factor H for treatment of diseases

    The Regents of the University of Colorado, a Body Corporate · Granted Oct 29, 2013 · Expires Oct 24, 2033

    granted

  2. US 8569448

    NMDAR biomarkers for diagnosis and treatment of traumatic brain injury and other disorders

    GRACE LABORATORIES, LLC · Granted Oct 29, 2013 · Expires Oct 24, 2033

    granted

  3. US 8568977

    Compositions and methods for diagnosis and treatment of tumors

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Oct 29, 2013 · Expires Oct 24, 2033

    granted

  4. US 8563595

    Treatment of cancer with complex organic-inorganic pigment compositions

    The Board of Regents of the University of Texas System · Granted Oct 22, 2013 · Expires Oct 17, 2033

    granted

  5. US 8557290

    Multifunction nanoconjugates for imaging applications and targeted treatment

    Northwestern University · Granted Oct 15, 2013 · Expires Oct 10, 2033

    granted

  6. US 8557298

    Medicaments for chemotherapeutic treatment of disease

    Provectus Pharmatech, Inc. · Granted Oct 15, 2013 · Expires Oct 10, 2033

    granted

  7. US 8541373

    BChE albumin fusions for the treatment of cocaine abuse

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Sep 24, 2013 · Expires Sep 19, 2033

    granted

  8. US 8541456

    Roflumilast for the treatment of diabetes mellitus type 2

    TAKEDA GMBH · Granted Sep 24, 2013 · Expires Sep 19, 2033

    granted

  9. US 8541403

    Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) for use in treatment of diseases associated with a PTEN deficiency

    BIOMARIN PHARMACEUTICAL INC. · Granted Sep 24, 2013 · Expires Sep 19, 2033

    granted

  10. US 8541371

    Treatment of conditions related to cecal ligation shock

    The Regents of the University of California · Granted Sep 24, 2013 · Expires Sep 19, 2033

    granted

  11. US 8536148

    Disabling autophagy as a treatment for lysosomal storage diseases

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Sep 17, 2013 · Expires Sep 12, 2033

    granted

  12. US 8530466

    Use of 2,4-pyrimidinediamines for the treatment of atherosclerosis

    Rigel Pharmaceuticals, Inc. · Granted Sep 10, 2013 · Expires Sep 5, 2033

    granted

  13. US 8524655

    Use of SCF and G-CSF in the treatment of cerebral ischemia and neurological disorders

    Northwestern University · Granted Sep 3, 2013 · Expires Aug 29, 2033

    granted

  14. US 8518390

    Treatment of stroke and other acute neural degenerative disorders via intranasal administration of umbilical cord-derived cells

    Advanced Technologies and Regenerative Medicine, LLC · Granted Aug 27, 2013 · Expires Aug 22, 2033

    granted

  15. US 8518870

    Compositions and methods for cancer treatment using targeted carbon nanotubes

    The Board of Regents of the University of Oklahoma · Granted Aug 27, 2013 · Expires Aug 22, 2033

    granted

  16. US 8518980

    Treatment of Duchenne muscular dystrophy

    Summit Corporation Plc · Granted Aug 27, 2013 · Expires Aug 22, 2033

    granted

  17. US 8512964

    Targets for treatment of hypercholesterolemia

    The Regents of the University of California · Granted Aug 20, 2013 · Expires Aug 15, 2033

    granted

  18. AU 2012210489

    IL17 and IFN-gamma inhibition for the treatment of autoimmune inflammation

    4SC DISCOVERY GMBH [DE] · Granted Aug 15, 2013 · Expires Aug 10, 2033

    granted

  19. AU 2012210491

    IL17 and IFN-gamma inhibition for the treatment of autoimmune inflammation

    4SC DISCOVERY GMBH [DE] · Granted Aug 15, 2013 · Expires Aug 10, 2033

    granted

  20. US 8507447

    Treatments for gastrointestinal disorders

    IRONWOOD PHARMACEUTICALS, INC. · Granted Aug 13, 2013 · Expires Aug 8, 2033

    granted

  21. US 8506959

    Prevention and treatment of synucleinopathic and amyloidogenic disease

    The Regents of the University of California · Granted Aug 13, 2013 · Expires Aug 8, 2033

    granted

  22. US 8501695

    Tissue kallikrein for the treatment of diseases associated with amyloid protein

    DiaMedica Inc. · Granted Aug 6, 2013 · Expires Aug 1, 2033

    granted

  23. US 8501953

    PKM2 modulators for use in the treatment of cancer

    Agios Pharmaceuticals, Inc. · Granted Aug 6, 2013 · Expires Aug 1, 2033

    granted

  24. US 8501766

    Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Aug 6, 2013 · Expires Aug 1, 2033

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.